Merck & Co. Updates Impact on Manufacturing from Network Cyberattack
As part of its second-quarter earnings report on July 28, 2017, Merck & Co., provided an update on the impact on its operations resulting from a June 27, 2017, network cyberattack that led to a disruption of its worldwide operations, including manufacturing, research and sales operations. The company said it does not yet know the magnitude of the impact of the disruption, which remains ongoing in certain operations, it continues to work to minimize the effects.
Merck & Co. said it is in the process of restoring its manufacturing operations. To date, Merck has largely restored its packaging operations and has partially restored its formulation operations. The company is in the process of restoring its active pharmaceutical ingredient operations, but is not yet producing bulk product. The company’s external manufacturing was not impacted. Throughout this time, Merck said it has continued to fulfill orders and ship product.
The company said it is “confident” in the continuous supply of key products such as its cancer drug Keytruda (pembrolizumab), its diabetes drug Januvia (sitagliptin), and its hepatitis C drug Zepatier (elbasvir and grazoprevir). In addition, Merck said it does not currently expect a significant impact to sales of its other top products; however, the company said it anticipates that it will have temporary delays in fulfilling orders for certain other products in certain markets.
Source: Merck & Co.